A phase 1 dose-escalation study to examine the safety and tolerability of LY2603618 administered 1 day after pemetrexed 500 mg/m2 every 21 days in patients with cancer

被引：0
|
作者：
Weiss, G. [1 ]
Donehower, R. [2 ]
Westin, E. [3 ]
Bence, A. [4 ]
Hynes, S. [5 ]
Hurt, K. [6 ]
机构：
[1] TGEN Clin Res, Canc & Cell Biol Div, Scottsdale, AZ USA
[2] Johns Hopkins Univ, Med Ctr, Baltimore, MD 21218 USA
[3] Eli Lilly & Co, Med Oncol Exploratory Preclin, Indianapolis, IN 46285 USA
[4] Eli Lilly & Co, Oncol, Indianapolis, IN 46285 USA
[5] Eli Lilly & Co, Program Phase, Indianapolis, IN 46285 USA
[6] Eli Lilly & Co, Clin Oncol, Indianapolis, IN 46285 USA
来源：
EJC SUPPLEMENTS | 2010年 / 8卷 / 07期
关键词：
D O I：
10.1016/S1359-6349(10)72223-0
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：165 / 165
页数：1
相关论文
共 50 条
  • [21] A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY AND TOLERABILITY STUDY OF NC762 IN SUBJECTS WITH ADVANCED OR METASTATIC SOLID TUMORS
    Myint, Han
    Shah, Satish
    Gutierrez, Martin
    Zsiros, Emese
    Nelson, Megan
    Zeidan, Stephanie
    Myrthil, Nadia
    Morawski, Aaron
    Barbu, Alina
    Shaik, Jahangheer
    Zhou, Chelsea
    Kanellopoulou, Chrysi
    Copeland, Ron
    Cusumano, Zachary
    Flies, Dallas
    Langermann, Solomon
    Lorusso, Patricia
    Odunsi, Kunle
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A781 - A781
  • [22] A randomized phase II study of 500 mg/m2 and 1,000 mg/m2 of pemetrexed in patients (pts) with locally advanced or metastatic non-small cell lung cancer (NSCLC) who had prior chemotherapy
    Ichinose, Y.
    Nakagawa, K.
    Tamura, T.
    Kubota, K.
    Yamamoto, N.
    Adachi, S.
    Nambu, Y.
    Nishiwaki, Y.
    Saijo, N.
    Fukuoka, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [23] Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancer
    Shunsuke Kondo
    Masaomi Tajimi
    Tomohiko Funai
    Koichi Inoue
    Hiroya Asou
    Vinay Kumar Ranka
    Volker Wacheck
    Toshihiko Doi
    Investigational New Drugs, 2020, 38 : 1836 - 1845
  • [24] Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancer
    Kondo, Shunsuke
    Tajimi, Masaomi
    Funai, Tomohiko
    Inoue, Koichi
    Asou, Hiroya
    Ranka, Vinay Kumar
    Wacheck, Volker
    Doi, Toshihiko
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (06) : 1836 - 1845
  • [25] A phase I dose-escalation study to a predefined dose of a transforming growth factor-β1 monoclonal antibody (TβM1) in patients with metastatic cancer
    Cohn, Allen
    Lahn, Michael M.
    Williams, Kristen E.
    Cleverly, Ann L.
    Pitou, Celine
    Kadam, Sunil K.
    Farmen, Mark W.
    Desaiah, Durisala
    Raju, Robert
    Conkling, Paul
    Richards, Donald
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2014, 45 (06) : 2221 - 2231
  • [26] Cohort 1 of a Phase 1, Double-Blind, Placebo-Controlled, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of ISIS 333611 Administered Intrathecally to Patients with Familial ALS Due to SOD1 Gene Mutations
    Miller, Timothy
    Smith, Richard
    Aggarwal, Swati
    Pestronk, Alan
    David, William
    Rothstein, Jeffrey
    Simpson, Ericka
    Brooks, Benjamin
    Bakst, Isaac
    Andres, Patricia
    Allred, Peggy
    Alexander, Katie
    Bishop, Kathie
    Bennett, C. Frank
    Cudkowicz, Merit
    NEUROLOGY, 2011, 76 (09) : A664 - A664
  • [27] A Phase 1/2 Open-label, Multiple-dose, Dose-escalation Clinical Trial of the Safety and Tolerability of GTX-102 in Pediatric Patients with Angelman Syndrome
    Sell, E.
    Servais, L.
    Harijan, P.
    Stromatt, S.
    Brandabur, M.
    Berry-Kravis, E.
    ANNALS OF NEUROLOGY, 2022, 92 : S163 - S163
  • [28] Results of a Phase 1, Double-Blind, Placebo-Controlled, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of ISIS 333611 Administered Intrathecally to Patients with Familial ALS Due to SOD1 Gene Mutations
    Miller, Timothy
    Smith, Richard
    Pestronk, Alan
    David, William
    Rothstein, Jeffrey
    Simpson, Ericka
    Andres, Patricia
    Mahoney, Katy
    Allred, Peggy
    Alexander, Katie
    Bishop, Kathie
    Schoenfeld, David
    Macklin, Erin
    Norris, Daniel
    Bennett, C.
    Cudkowicz, Merit
    NEUROLOGY, 2012, 78
  • [29] A phase 1/2, open-label, dose-escalation, safety and tolerability study of NC410 in subjects with advanced or metastatic solid tumors.
    Gutierrez, Martin
    Janku, Filip
    Tian, Linjie
    Luke, Jason J.
    Shum, Elaine
    Shin, John
    Weiss, Ido
    Liu, Linda N.
    Files, Dallas
    Langermann, Solomon
    Myint, Han
    Bilusic, Marijo
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [30] Phase 1b/2a Open-Label, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of SNS01-T Administered by Intravenous Infusion in Patients with Relapsed or Refractory Multiple Myeloma
    Lust, John A.
    Usmani, Saad Z.
    Hamadani, Mehdi
    Barranco, Charles
    Lacy, Martha Q.
    Dispenzieri, Angela
    Gertz, Morie A.
    Dingli, David
    Russell, Stephen
    Buadi, Francis K.
    Zeldenrust, Steven R.
    Hayman, Suzanne R.
    Rajkumar, S. Vincent
    Kumar, Shaji K.
    Thompson, John
    Taylor, Catherine A.
    Dondero, Richard
    BLOOD, 2012, 120 (21)
12345